Type Whole antibody Target Guanylate cyclase 2C ATC code none | Source Human Routes of
administration Intravenous Legal status Experimental | |
Indusatumab vedotin (MLN-0264) is an antibody-drug conjugate that is under development for the treatment of pancreatic cancer and other gastrointestinal cancers. It consists of a monoclonal antibody (indusatumab) that targets the enzyme guanylate cyclase 2C which is present in some cancers, linked to an average of three to four molecules of the chemotherapeutic agent monomethyl auristatin E (MMAE).
It is in Phase II clinical trials as of February 2016.
References
Indusatumab vedotin Wikipedia(Text) CC BY-SA